Urinary Incontinence in Children

Urinary incontinence in children covers two related but distinct problems: daytime incontinence (repeated daytime wetting in a child 5 years of age or older) and nocturnal enuresis (bedwetting beyond the age most children achieve night-time dryness — beyond 5 years of age for girls and 6 years of age for boys). Most children achieve daytime toilet training by about 3 years of age, with a wide normal range, and continence continues to mature over the following years — a large share of both daytime wetting and bedwetting resolves on its own with time, which shapes how aggressively to intervene and how to counsel families on timing. The single most important branch point in management is whether nocturnal enuresis occurs in isolation (monosymptomatic) or together with daytime lower urinary tract symptoms (non-monosymptomatic) — the two need different workups and different first-line treatment sequencing.^[1]

Daytime incontinence

Defined as repeated daytime voiding into clothing at least twice weekly for at least 3 consecutive months in a child 5 years of age or older. It is considered a clinical problem in a child 4 years of age or older who wets daily (primary) or who relapses after at least 6 consecutive symptom-free months (secondary).

Nocturnal enuresis

Bedwetting, including during naps, occurring more than twice weekly beyond the age of 5 for girls and 6 for boys. In primary enuresis, night-time bladder control has never been achieved; in secondary enuresis, wetting resumes after at least 6 months of established dryness — secondary enuresis carries a higher likelihood of an identifiable trigger and deserves a more careful search for a cause (see Assessment and Diagnosis).

Causes of daytime incontinence

Causes of enuresis

Developmental delay, a family history of enuresis, and obstructive sleep apnea are all recognized contributors to primary enuresis; treating sleep-disordered breathing (including adenotonsillectomy where indicated) has been observed to improve monosymptomatic nocturnal enuresis in children who have both conditions.^[2]

• Family history of urinary incontinence or enuresis.
• Functional constipation — one of the most common and correctable contributors to both daytime and night-time incontinence.
• Developmental delay or a neurodevelopmental disorder.
• Obstructive sleep apnea or habitual snoring.
• Male sex (primary enuresis is more common in boys; daytime incontinence is more common in girls).
• An unsupportive or punitive caregiver response to wetting episodes, which predicts poorer engagement with treatment rather than causing the incontinence itself.
• Prior urinary tract infection or urologic surgery.
• Never having achieved sustained dryness (primary) versus a period of established dryness followed by relapse (secondary) — each points toward a different set of likely causes.

History

• Family history of urinary incontinence or enuresis — often present.
• Bowel habits and any symptoms of constipation — closely linked to incontinence through reduced functional bladder capacity from a loaded rectum.
• The detailed pattern of wetting: daytime, night-time, or both; frequency; approximate volume; whether the child has ever achieved sustained dryness (primary vs. secondary).
• History of urinary tract infections or prior urologic surgery.
• Daytime voiding frequency and any urgency, straining, or a weak stream.
• Snoring or other symptoms of sleep-disordered breathing.
• Psychological status of the child and family dynamics, including how the family currently responds to wetting episodes.

Physical examination

• Perineal sensation, perineal reflexes, and sphincter tone, to screen for a neurogenic bladder.
• Genitalia, particularly the urethral meatus, to screen for anatomical causes such as meatal stenosis (boys) or labial fusion (girls).
• The lower spine, for signs of occult spinal dysraphism (hair tuft, dimple, pigmented lesion, subcutaneous lipoma, gluteal cleft asymmetry) — refer to pediatric neurosurgery if present.
• Direct observation of voiding, when feasible, to assess the urinary stream.
• Abdominal examination for a palpable fecal mass suggesting significant constipation.

Investigations

• A voiding and/or bowel-movement diary kept by the family — the single most useful tool for characterizing the actual pattern.
• Urinalysis and urine culture in every child being assessed for incontinence.
• No further investigation is necessary for straightforward primary enuresis with a normal history, normal exam, and normal urinalysis.^[3]
• Renal and bladder ultrasound plus a voiding cystourethrogram are reserved for children with a history of urinary tract infections, to look for vesicoureteral reflux, partial urethral obstruction, or a neurogenic bladder — refer to urology if the voiding cystourethrogram is abnormal.

Interpreting the history

Certain findings point toward a specific mechanism and should shape the assessment rather than being treated as incidental detail. A large volume of urine passed early in the night is typical for uncomplicated bedwetting; a variable volume, or urine passed more than once a night, raises concern for an underlying overactive bladder. Bedwetting every single night is less likely to resolve on its own than infrequent bedwetting. Daytime frequency, urgency, straining, or pain with voiding all point toward a bladder disorder rather than isolated night-time enuresis. Constipation and soiling are common, frequently under-recognized comorbidities — soiling in particular is usually secondary to fecal impaction rather than a primary behavioural problem. Inadequate daytime fluid intake can mask an underlying bladder problem and impede the development of normal bladder capacity, so ask about it directly rather than assuming low daytime output is reassuring. Practical barriers — a shared bedroom, difficulty accessing a bathroom at night, or family circumstances that make an alarm hard to use consistently — should be identified early, since they change which treatment is realistic for a given family.

• Identify and manage any serious underlying cause (structural, neurologic, infectious, or endocrine) before treating as functional incontinence.
• Treat constipation, since resolving it frequently improves daytime and night-time bladder symptoms directly.
• Reduce the frequency of daytime incontinence episodes and increase the number of dry nights, working toward complete, durable dryness.
• Choose a treatment approach the child and family can realistically sustain, since motivation and consistent participation are the strongest predictors of success.
• Avoid treatment-related harm — most importantly, prevent desmopressin-associated water intoxication and hyponatremia through correct fluid-restriction counselling.
• Provide ongoing reassurance and practical guidance to reduce the distress and social impact incontinence causes for the child.

Caregiver approach and general counselling

• Advise caregivers to avoid humiliating or punishing the child for wetting episodes — an intolerant caregiver attitude predicts early dropout from treatment, and there is no good evidence that enuresis itself reflects a behavioural or psychological problem.
• Use positive reinforcement: reassurance, a diary of dry days/nights, and easy, unhindered access to a bathroom at home and school.
• Have the child avoid excessive fluid intake within 2 hours of bedtime and empty the bladder immediately before going to sleep.
• Encourage the child not to defer or "hold" urination during the day.
• For daytime incontinence, use bladder training: a scheduled voiding routine (for example, every 2-3 hours) and pelvic floor/abdominal muscle exercises.

Treat constipation

Functional constipation is a major, frequently overlooked contributor to both daytime incontinence and nocturnal enuresis — a loaded rectum reduces effective bladder capacity and can trigger detrusor overactivity. Screen for it in every child with incontinence and treat it concurrently with bladder-directed therapy; see the Constipation in Children chapter for disimpaction and maintenance laxative dosing. Resolving constipation alone is often enough to substantially improve or resolve associated bladder symptoms.

Enuresis alarm therapy

Alarm therapy is the preferred first-line treatment for monosymptomatic nocturnal enuresis and has the strongest evidence base of any single intervention, reducing the average number of wet nights compared with no treatment and — unlike desmopressin — producing durable dryness with a low relapse rate once successful.^[4] The alarm is a small, moisture-sensitive sensor worn in the underwear or on an absorbent pad that vibrates or sounds at the very first sign of voiding. Because children with enuresis are often deep sleepers, the caregiver frequently needs to be the one who wakes the child when the alarm sounds; the child then finishes voiding in the toilet and returns to bed after changing into dry underwear/bedding. Alarm therapy tends to work best in children with normal urine output and a small or normal bladder capacity, and may be tried from about 5 years of age in a motivated, well-supported family, with the best results generally seen from about 7 years of age onward. Response builds gradually — give an adequate trial (generally at least 6-8 weeks of consistent use) before concluding it has failed. Adding dry-bed training (a strict schedule for waking the child overnight until they learn to wake independently) or overlearning (having the child drink extra fluid before bed once the alarm is producing dry nights, while continuing to use the alarm) after initial dryness is achieved lowers the relapse rate compared with stopping the alarm alone.^[2]

Complementary and other non-pharmacologic approaches

There is no good evidence of effectiveness for hypnosis, chiropractic manipulation, faradization (electrical stimulation to the genital area), or homeopathy — these should not be recommended as a substitute for alarm therapy or medication. There is some evidence that transcutaneous parasacral electrical nerve stimulation, functional magnetic stimulation, laser acupuncture, or limiting evening milk intake (to reduce hypercalciuria) may modestly improve response or reduce relapse when added to standard treatment, though the trial base behind each remains small.^[2]

Pregnancy and breastfeeding

This chapter covers prepubertal and adolescent children; pregnancy is not a consideration for most patients. In a post-menarchal adolescent, confirm pregnancy status before starting or continuing desmopressin or an antimuscarinic — the pediatric dosing and safety information in this chapter assumes a non-pregnant patient, desmopressin's hyponatremia risk has not been specifically studied for this indication in pregnancy, and antimuscarinic agents are not well characterized in pregnancy. If pregnancy is identified, manage under adult obstetric/urology guidance rather than continuing pediatric incontinence dosing unchanged. Breastfeeding is not a relevant consideration for a patient being treated for pediatric urinary incontinence.

Young children

Given the high rate of spontaneous resolution before school age, avoid starting alarm therapy or medication before about 5-6 years of age unless daytime symptoms or a red flag are present — reassurance and expectation-setting alone are appropriate first-line management in a younger child with isolated bedwetting.

Developmental delay / neurodevelopmental disorders

Developmental delay is a recognized predictor of a poorer response to both alarm therapy and desmopressin. These children can still be offered treatment, but set realistic expectations with the family, allow a longer trial before judging response, and consider earlier referral if progress stalls.

Obstructive sleep apnea

Ask about snoring and witnessed apneas in any child with monosymptomatic nocturnal enuresis that is not responding as expected — treating obstructive sleep apnea, including adenotonsillectomy when indicated, has been observed to improve or resolve associated enuresis, and a sleep medicine or otolaryngology referral is appropriate when sleep-disordered breathing is suspected.^[2]

Renal, hepatic, and cardiac disease

Desmopressin is contraindicated in hyponatremia, severe liver disease, nephrosis, and cardiac insufficiency associated with fluid-retention risk, and should be used with caution — ideally with specialist input — in cystic fibrosis, heart failure, and other conditions that predispose to fluid or electrolyte imbalance, since all of these increase the risk of dangerous hyponatremia on desmopressin.^[7]

Antimuscarinic cautions

Avoid oxybutynin, tolterodine, solifenacin, and propiverine in narrow-angle glaucoma, significant gastrointestinal obstruction or motility disorders, and myasthenia gravis, consistent with standard antimuscarinic precautions.

• Keep a voiding and/or bowel diary throughout treatment — the most useful single tool for tracking response and guiding dose/therapy changes.
• For alarm therapy, review progress with the family at regular intervals (for example, every 2-4 weeks); an adequate trial is generally 6-8 weeks before judging effectiveness, and initial dryness should be consolidated with continued use, dry-bed training, or overlearning before stopping.
• For desmopressin, reinforce fluid-restriction counselling at every visit or refill, and plan a treatment interruption of about 1 week roughly every 3 months to confirm ongoing need before continuing for a further course.
• Ask specifically about prodromal hyponatremia symptoms (headache, nausea, vomiting) at every desmopressin follow-up, and instruct the family to stop the dose and seek urgent care immediately if these occur.
• For antimuscarinic therapy, reassess at about 4 weeks for effect and tolerability (dry mouth, constipation, drowsiness), and actively monitor bowel habits given the constipating effect of these agents.
• Reassess constipation status at every visit, since ongoing bowel dysfunction undermines the response to bladder-directed therapy.
• Track dryness against the child's own baseline rather than against peers, and continue positive reinforcement throughout.

1. Confirm alarm therapy was used correctly and consistently for an adequate trial (generally at least 6-8 weeks) with caregiver participation in waking the child, before concluding it has failed.
2. Confirm desmopressin was taken correctly (timing, fluid restriction) and titrated to the maximum dose before concluding it has failed.
3. Reassess for and treat occult constipation, even if not spontaneously reported by the family.
4. Screen for previously unreported overactive bladder/daytime symptoms, sleep-disordered breathing (snoring, witnessed apneas), and social/emotional stressors.
5. If nocturnal polyuria and reduced bladder capacity coexist, or if enuresis relapsed after single-modality treatment, move to combination therapy — desmopressin plus alarm, or desmopressin plus an antimuscarinic.
6. If genuinely refractory to combination therapy, refer to pediatric urology or nephrology for further investigation and specialist-directed options, including tricyclic antidepressant therapy under close monitoring.

• Starting pharmacotherapy before addressing constipation, missing a bowel-management opportunity that alone resolves many cases.
• Failing to counsel fluid restriction around desmopressin dosing — the single highest-stakes safety gap, since untreated water intoxication can cause seizures.
• Using an intranasal desmopressin formulation for primary nocturnal enuresis — contraindicated in Canada given a materially higher hyponatremia risk than with oral formulations.
• Abandoning alarm therapy too early — response builds gradually over weeks, and stopping after only a few nights without improvement discards the treatment most likely to produce durable dryness.
• Treating non-monosymptomatic enuresis (daytime symptoms present) the same as monosymptomatic enuresis — daytime symptoms need urotherapy, with or without an antimuscarinic, addressed as part of the same plan.
• Punishing or shaming the child for wetting episodes — this undermines motivation and predicts treatment dropout.
• Missing red-flag findings (new severe daytime symptoms, spinal dysraphism signs, straining/weak stream) by assuming straightforward primary enuresis without a proper history and exam.
• Prescribing an antimuscarinic without addressing constipation risk, since these agents can worsen pre-existing constipation and undercut the exact bowel-management strategy that helps bladder symptoms.

How to use this table: Doses are pediatric doses (generally 5 years of age and older unless noted) and require patient-specific confirmation, including renal/hepatic adjustment and weight-based dosing where applicable. Select any drug name to open its complete Pharmasist Drug Database page.

Antidiuretic hormone analogues

First-line pharmacotherapy for monosymptomatic nocturnal enuresis. Oral formulations only.

Anticholinergics / antimuscarinics (antispasmodics)

For daytime urgency/incontinence from detrusor overactivity (urge syndrome, overactive bladder), or combined with desmopressin for enuresis refractory to either agent alone.

Tricyclic antidepressants (specialist-directed, 3rd-line option)

Evidence note: Drug inventory, dosing, contraindications, and comments verified against current Health Canada-regulated desmopressin product monographs, the ICCS 2020 and 2016 standardization documents, and the 2021 CUA/PUC guideline for bladder dysfunction in children.^[7][2][3]